Does the media favor AKTS or ACAD?

In the previous week, ACADIA Pharmaceuticals had 12 more articles in the media than Aktis Oncology. MarketBeat recorded 19 mentions for ACADIA Pharmaceuticals and 7 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.98 beat ACADIA Pharmaceuticals' score of 0.73 indicating that Aktis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 7 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is DYN or AKTS more profitable?

Aktis Oncology's return on equity of 0.00% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dyne Therapeutics N/A -64.30% -50.33% Aktis Oncology N/A N/A N/A

Does the media favor DYN or AKTS?

In the previous week, Aktis Oncology had 4 more articles in the media than Dyne Therapeutics. MarketBeat recorded 7 mentions for Aktis Oncology and 3 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.25 beat Aktis Oncology's score of 0.98 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aktis Oncology 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AKTS or CELC more profitable?

Aktis Oncology's return on equity of 0.00% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Celcuity N/A -250.68% -50.23%

Does the media refer more to AKTS or CELC?

In the previous week, Celcuity had 13 more articles in the media than Aktis Oncology. MarketBeat recorded 20 mentions for Celcuity and 7 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.98 beat Celcuity's score of 0.84 indicating that Aktis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 7 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Is AKTS or RLAY more profitable?

Aktis Oncology's return on equity of 0.00% beat Relay Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Relay Therapeutics N/A -42.27% -38.67%

Does the media prefer AKTS or RLAY?

In the previous week, Relay Therapeutics had 4 more articles in the media than Aktis Oncology. MarketBeat recorded 11 mentions for Relay Therapeutics and 7 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.98 beat Relay Therapeutics' score of 0.95 indicating that Aktis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ELVN or AKTS more profitable?

Aktis Oncology's return on equity of 0.00% beat Enliven Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Enliven Therapeutics N/A -18.55% -18.09% Aktis Oncology N/A N/A N/A

Does the media prefer ELVN or AKTS?

In the previous week, Enliven Therapeutics had 1 more articles in the media than Aktis Oncology. MarketBeat recorded 8 mentions for Enliven Therapeutics and 7 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.98 beat Enliven Therapeutics' score of 0.81 indicating that Aktis Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Aktis Oncology 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aktis Oncology (AKTS) Competitors

$24.93 +1.14 (+4.79%)

Closing price 04:00 PM Eastern

Extended Trading

$25.02 +0.09 (+0.38%)

As of 07:34 PM Eastern

Compare

AKTS vs. ACAD, DYN, CELC, RLAY, and ELVN

Should you buy Aktis Oncology stock or one of its competitors? Aktis Oncology's main competitors and comparable companies include ACADIA Pharmaceuticals (ACAD), Dyne Therapeutics (DYN), Celcuity (CELC), Relay Therapeutics (RLAY), and Enliven Therapeutics (ELVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aktis Oncology compare to ACADIA Pharmaceuticals?

Aktis Oncology (NASDAQ:AKTS) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

Aktis Oncology currently has a consensus price target of $34.60, suggesting a potential upside of 38.79%. ACADIA Pharmaceuticals has a consensus price target of $33.69, suggesting a potential upside of 19.31%. Given Aktis Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Aktis Oncology is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
ACADIA Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82

ACADIA Pharmaceuticals has higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	204.81	-$63.73M	-$0.38	N/A
ACADIA Pharmaceuticals	$1.07B	4.54	$391M	$2.22	12.72

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Aktis Oncology's net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Aktis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 3.3% of Aktis Oncology shares are owned by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, ACADIA Pharmaceuticals had 12 more articles in the media than Aktis Oncology. MarketBeat recorded 19 mentions for ACADIA Pharmaceuticals and 7 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.98 beat ACADIA Pharmaceuticals' score of 0.73 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	7 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ACADIA Pharmaceuticals beats Aktis Oncology on 11 of the 16 factors compared between the two stocks.

How does Aktis Oncology compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Aktis Oncology (NASDAQ:AKTS) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

Aktis Oncology's return on equity of 0.00% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.30%	-50.33%
Aktis Oncology	N/A	N/A	N/A

Dyne Therapeutics presently has a consensus price target of $34.42, indicating a potential upside of 33.92%. Aktis Oncology has a consensus price target of $34.60, indicating a potential upside of 38.79%. Given Aktis Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Aktis Oncology is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Aktis Oncology has higher revenue and earnings than Dyne Therapeutics. Aktis Oncology is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A
Aktis Oncology	$6.50M	204.81	-$63.73M	-$0.38	N/A

In the previous week, Aktis Oncology had 4 more articles in the media than Dyne Therapeutics. MarketBeat recorded 7 mentions for Aktis Oncology and 3 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.25 beat Aktis Oncology's score of 0.98 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aktis Oncology	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are held by institutional investors. 9.5% of Dyne Therapeutics shares are held by company insiders. Comparatively, 3.3% of Aktis Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Aktis Oncology beats Dyne Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Aktis Oncology compare to Celcuity?

Aktis Oncology (NASDAQ:AKTS) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Aktis Oncology's return on equity of 0.00% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Celcuity	N/A	-250.68%	-50.23%

In the previous week, Celcuity had 13 more articles in the media than Aktis Oncology. MarketBeat recorded 20 mentions for Celcuity and 7 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.98 beat Celcuity's score of 0.84 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celcuity	7 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Aktis Oncology currently has a consensus target price of $34.60, indicating a potential upside of 38.79%. Celcuity has a consensus target price of $153.64, indicating a potential upside of 67.00%. Given Celcuity's higher probable upside, analysts plainly believe Celcuity is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Aktis Oncology has higher revenue and earnings than Celcuity. Aktis Oncology is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	204.81	-$63.73M	-$0.38	N/A
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

28.8% of Aktis Oncology shares are held by institutional investors. Comparatively, 63.3% of Celcuity shares are held by institutional investors. 3.3% of Aktis Oncology shares are held by insiders. Comparatively, 13.3% of Celcuity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Aktis Oncology beats Celcuity on 8 of the 14 factors compared between the two stocks.

How does Aktis Oncology compare to Relay Therapeutics?

Aktis Oncology (NASDAQ:AKTS) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

Aktis Oncology's return on equity of 0.00% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Relay Therapeutics	N/A	-42.27%	-38.67%

28.8% of Aktis Oncology shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 3.3% of Aktis Oncology shares are held by company insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aktis Oncology has higher earnings, but lower revenue than Relay Therapeutics. Aktis Oncology is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	204.81	-$63.73M	-$0.38	N/A
Relay Therapeutics	$15.35M	283.53	-$276.48M	-$1.57	N/A

Aktis Oncology presently has a consensus target price of $34.60, indicating a potential upside of 38.79%. Relay Therapeutics has a consensus target price of $25.83, indicating a potential upside of 30.08%. Given Aktis Oncology's stronger consensus rating and higher probable upside, equities research analysts plainly believe Aktis Oncology is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86

In the previous week, Relay Therapeutics had 4 more articles in the media than Aktis Oncology. MarketBeat recorded 11 mentions for Relay Therapeutics and 7 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.98 beat Relay Therapeutics' score of 0.95 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Relay Therapeutics beats Aktis Oncology on 8 of the 15 factors compared between the two stocks.

How does Aktis Oncology compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Aktis Oncology (NASDAQ:AKTS) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Aktis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Enliven Therapeutics currently has a consensus target price of $72.67, indicating a potential upside of 23.54%. Aktis Oncology has a consensus target price of $34.60, indicating a potential upside of 38.79%. Given Aktis Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Aktis Oncology is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Enliven Therapeutics had 1 more articles in the media than Aktis Oncology. MarketBeat recorded 8 mentions for Enliven Therapeutics and 7 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.98 beat Enliven Therapeutics' score of 0.81 indicating that Aktis Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Aktis Oncology	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aktis Oncology has higher revenue and earnings than Enliven Therapeutics. Aktis Oncology is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Aktis Oncology	$6.50M	204.81	-$63.73M	-$0.38	N/A

Aktis Oncology's return on equity of 0.00% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-18.55%	-18.09%
Aktis Oncology	N/A	N/A	N/A

Summary

Aktis Oncology beats Enliven Therapeutics on 10 of the 13 factors compared between the two stocks.

Get Aktis Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKTS vs. The Competition

Export

Metric	Aktis Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.27B	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-65.61	10.67	269.06	25.28
Price / Sales	204.81	1,294.08	602.43	91.76
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	-8.63	16.78	12.91	6.24
Net Income	-$63.73M	-$13.32M	$3.45B	$347.60M
7 Day Performance	3.32%	1.74%	1.12%	1.07%
1 Month Performance	-0.95%	1.60%	1.79%	1.03%
1 Year Performance	N/A	56.43%	67.69%	20.77%

Aktis Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKTS Aktis Oncology	3.0643 of 5 stars	$24.93 +4.8%	$34.60 +38.8%	N/A	$1.27B	$6.50M	N/A	76	News Coverage Earnings Report
ACAD ACADIA Pharmaceuticals	4.5548 of 5 stars	$29.39 +0.6%	$33.31 +13.3%	+12.8%	$5.06B	$1.07B	13.24	510	Analyst Forecast
DYN Dyne Therapeutics	3.7419 of 5 stars	$26.50 +1.0%	$34.42 +29.9%	+112.1%	$4.95B	N/A	N/A	100
CELC Celcuity	3.6751 of 5 stars	$90.79 -2.1%	$155.18 +70.9%	+65.4%	$4.43B	N/A	N/A	40	Trending News Earnings Report Analyst Forecast Gap Down
RLAY Relay Therapeutics	3.3681 of 5 stars	$19.94 +0.9%	$25.58 +28.3%	+482.7%	$4.37B	$15.35M	N/A	330	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKTS) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aktis Oncology (AKTS) Competitors

AKTS vs. ACAD, DYN, CELC, RLAY, and ELVN

How does Aktis Oncology compare to ACADIA Pharmaceuticals?

Summary

How does Aktis Oncology compare to Dyne Therapeutics?

Summary

How does Aktis Oncology compare to Celcuity?

Summary

How does Aktis Oncology compare to Relay Therapeutics?

Summary

How does Aktis Oncology compare to Enliven Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTS vs. The Competition

Aktis Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aktis Oncology (AKTS) Competitors

AKTS vs. ACAD, DYN, CELC, RLAY, and ELVN

How does Aktis Oncology compare to ACADIA Pharmaceuticals?

Do analysts prefer AKTS or ACAD?

Which has higher valuation and earnings, AKTS or ACAD?

Is AKTS or ACAD more profitable?

Do insiders and institutionals hold more shares of AKTS or ACAD?

Does the media favor AKTS or ACAD?

Summary

How does Aktis Oncology compare to Dyne Therapeutics?

Is DYN or AKTS more profitable?

Do analysts prefer DYN or AKTS?

Which has better earnings & valuation, DYN or AKTS?

Does the media favor DYN or AKTS?

Do insiders and institutionals believe in DYN or AKTS?

Summary

How does Aktis Oncology compare to Celcuity?

Is AKTS or CELC more profitable?

Does the media refer more to AKTS or CELC?

Do analysts rate AKTS or CELC?

Which has preferable valuation & earnings, AKTS or CELC?

Do insiders and institutionals have more ownership in AKTS or CELC?

Summary

How does Aktis Oncology compare to Relay Therapeutics?

Is AKTS or RLAY more profitable?

Do insiders and institutionals believe in AKTS or RLAY?

Which has better valuation and earnings, AKTS or RLAY?

Do analysts prefer AKTS or RLAY?

Does the media prefer AKTS or RLAY?

Summary

How does Aktis Oncology compare to Enliven Therapeutics?

Do insiders & institutionals believe in ELVN or AKTS?

Do analysts rate ELVN or AKTS?

Does the media prefer ELVN or AKTS?

Which has stronger earnings and valuation, ELVN or AKTS?

Is ELVN or AKTS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTS vs. The Competition

Aktis Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools